Yanni Xu

ORCID: 0000-0003-1539-0606
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cholesterol and Lipid Metabolism
  • Peroxisome Proliferator-Activated Receptors
  • Drug Transport and Resistance Mechanisms
  • Cancer, Lipids, and Metabolism
  • Kruppel-like factors research
  • Atherosclerosis and Cardiovascular Diseases
  • Sirtuins and Resveratrol in Medicine
  • Microbial Natural Products and Biosynthesis
  • Cytokine Signaling Pathways and Interactions
  • Lipoproteins and Cardiovascular Health
  • interferon and immune responses
  • Hippo pathway signaling and YAP/TAZ
  • Bone health and treatments
  • Natural product bioactivities and synthesis
  • Bone Metabolism and Diseases
  • Cancer Mechanisms and Therapy
  • Inflammatory mediators and NSAID effects
  • Tuberculosis Research and Epidemiology
  • Flavonoids in Medical Research
  • Drug-Induced Hepatotoxicity and Protection
  • Eicosanoids and Hypertension Pharmacology
  • S100 Proteins and Annexins
  • Monoclonal and Polyclonal Antibodies Research
  • RNA Interference and Gene Delivery
  • Cancer-related molecular mechanisms research

Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025

North Sichuan Medical University
2023

Sun Yat-sen Memorial Hospital
2023

Sun Yat-sen University
2023

Tianjin University of Science and Technology
2022

Shandong Agricultural University
2021

Foshan University
2021

Institute of Medicinal Plant Development
2017-2020

Academia Sinica
2020

Academy of Medical Sciences
2020

Abstract Aims Recent genome-wide association studies (GWAS) have identified that the JCAD locus is associated with risk of coronary artery disease (CAD) and myocardial infarction (MI). However, mechanisms whereby candidate gene confers remain unclear. We addressed whether how affects development atherosclerosis, common cause CAD. Methods results By mining data in Genotype-Tissue Expression (GTEx) database, we found CAD-associated variants at are linked to increased expression human arteries,...

10.1093/eurheartj/ehz303 article EN European Heart Journal 2019-05-03

Violaceotides B–E (1–4), four new cyclic tetrapeptides, along with seven known compounds, were identified from the sponge-associated Aspergillus insulicola IMB18-072 co-cultivated marine-derived Alternaria angustiovoidea IMB20-805. Their structures elucidated by extensive analysis of spectroscopic data, including HRESIMS, 1D and 2D NMR, MS/MS data. The absolute configurations determined advanced Marfey's method. Compounds 2, 3, violaceotide A (5) displayed selective antimicrobial activities...

10.1021/acs.jnatprod.3c01115 article EN Journal of Natural Products 2024-01-26

Rationale:Atherosclerosis is a chronic inflammatory and epigenetic disease that influenced by different patterns of blood flow.However, the mechanism whereby atheroprotective flow controls endothelial gene programming remains elusive.Here, we investigated possibility alters expression through mechanisms.Methods: En face staining western blot were used to detect protein expression.Real-time PCR was determine relative expression.RNA-sequencing human umbilical vein cells treated with siRNA...

10.7150/thno.21966 article EN cc-by Theranostics 2018-01-01

Abstract Nuclear receptor peroxisome proliferator-activated γ (PPARγ) plays an important role in the regulation of glucose homeostasis and lipid metabolism. However, current PPARγ-targeting drugs such as thiazolidinediones (TZDs) are associated with undesirable side effects. We identified a small molecular compound, F12016, selective PPARγ agonist by virtual screening, which showed moderate agonistic activity binding ability for PPARγ. F12016 did not activate other PPAR subtypes at 30 μM...

10.1038/srep09530 article EN cc-by Scientific Reports 2015-04-01

ABCA1 and scavenger receptor class B type I (SR-BI)/CD36 lysosomal integral membrane protein II analogous 1 (CLA-1) are the key transporter in reverse cholesterol transport (RCT). Increasing expression level of SR-BI/CLA-1 is antiatherogenic. The aim study was to find novel antiatherosclerotic agents upregulating from natural compounds. Using ABCA1p-LUC CLA-1p-LUC HepG2 cell lines, we found that rutaecarpine (RUT) triggered promoters CLA-1 genes. RUT increased vitro related liver X alpha...

10.1194/jlr.m044198 article EN cc-by Journal of Lipid Research 2014-06-08

Kruppel-like factor 2 (KLF2) is an important zinc-finger transcription that maintains endothelial homeostasis by its anti-inflammatory, -thrombotic, -oxidative, and -proliferative effects in cells. In light of the potent vasoprotective KLF2, modulating KLF2 expression or function could give rise to new therapeutic strategies treat cardiovascular diseases.High-throughput drug screening based on promoter luciferase reporter assay was performed screen activators. Real-time PCR western blot were...

10.1161/jaha.117.007134 article EN cc-by-nc-nd Journal of the American Heart Association 2017-12-01

The transcription factor Kruppel-like 2 (KLF2) is a critical anti-inflammatory and anti-atherogenic molecule in vascular endothelium. Enhancing KLF2 expression activity improves endothelial function prevents atherosclerosis. However, the pharmacological molecular regulators for are scarce. Using high-throughput luciferase reporter assay to screen activators, we have identified tannic acid (TA), polyphenolic compound, as potent activator that attenuates inflammation. Mechanistic studies...

10.1038/s41598-017-06803-x article EN cc-by Scientific Reports 2017-07-21

BACKGROUND: Atherosclerosis is the most common cause of cardiovascular diseases. Clinical studies indicate that loss-of-function ASGR1 (asialoglycoprotein receptor 1) significantly associated with lower plasma cholesterol levels and reduces disease risk. However, effect on atherosclerosis remains incompletely understood; whether inhibition causes liver injury controversial. Here, we comprehensively investigated effects underlying molecular mechanisms deficiency overexpression in mice....

10.1161/atvbaha.124.321076 article EN Arteriosclerosis Thrombosis and Vascular Biology 2024-10-10

Type 2 diabetes mellitus (T2DM) is a common chronic metabolic disease. Peroxisome proliferator-activated receptors (PPARs) play crucial roles in regulating glucolipid metabolism. Previous studies showed that E17241 could ameliorate atherosclerosis and lower fasting blood glucose levels ApoE

10.1016/j.biopha.2024.116220 article EN cc-by-nc-nd Biomedicine & Pharmacotherapy 2024-02-02

Aims Acute alcohol intoxication (AAI) caused by the intake of excessive is a harmful clinical condition and potentially life threatening. Therefore, there has been increasing attention on development anti-alcoholism products. In this study, we evaluated therapeutic benefits an product (Tengcha–Gegen Plant Solid Beverage, which contains Ampelopsis grossedentata, Pueraria Lobata, Hovenia dulcis Thunb, turmeric) in AAI mouse model. Methods The model was established through gavage. Male Kunming...

10.1177/1934578x251313877 article EN cc-by-nc Natural Product Communications 2025-01-01

Activation of liver X receptor (LXR) is associated with cholesterol metabolism and anti-inflammatory processes, which makes it beneficial to antiatherosclerosis therapy. Nevertheless, existing agonists that target LXR, for example TO901317, are related unwanted side effects. In the present study, using a screening method we identified IMB-808, displayed potent dual LXR<i>α</i>/<i>β</i> agonistic activity. vitro, IMB-808 effectively increased expressing quantity genes reverse transport...

10.1124/mol.116.105213 article EN Molecular Pharmacology 2017-01-13

The probability of cardiovascular events has been reported lower in rheumatoid arthritis (RA) patients treated with leflunomide.However, the anti-atherosclerotic and protective effects metabolism leflunomide are not explored.In this study, we assessed potential benefits on atherosclerosis revealed underlying mechanism.ApoE -/ -mice were fed a western diet (WD) alone or supplemented (20 mg/kg, oral gavage, once per day) for 12 weeks.Samples aorta, heart, liver, serum, macrophages collected.We...

10.7150/ijbs.93465 article EN cc-by-nc International Journal of Biological Sciences 2024-01-01

The ATP-binding cassette transporter A1 (ABCA1) is a membrane that directly contributes to high-density lipoprotein (HDL) biogenesis by mediating the cellular efflux of cholesterol and phospholipids lipid-poor apolipoprotein A-I.Therefore, identification novel upregulator ABCA1 would be beneficial for atherosclerosis prevention and/or therapy because its pivotal role in homeostasis HDL metabolism.In this study, high-throughput assay method upregulators was developed used screening synthetic...

10.1177/1087057108320545 article EN cc-by-nc-nd SLAS DISCOVERY 2008-07-02

ATP-binding cassette transporter A1 (ABCA1) is a key and receptor in promoting cholesterol efflux, increasing the expression level of ABCA1 antiatherogenic. In our previous study, rutaecarpine (RUT) was found to protect ApoE(-/-) mice from developing atherosclerosis through preferentially up-regulating expression. present work, series RUT derivatives were synthesized examined as up-regulators. Compounds CD1, CD6, BCD1-2 possess most potential activity antiatherosclerotic agents among all...

10.1021/ml500131a article EN ACS Medicinal Chemistry Letters 2014-06-24

Atherosclerosis is a chronic disease characterized by lipid deposition and inflammatory response. NOD-, LRR- pyrin domain-containing protein 3 (NLRP3) inflammasome-facilitated responses are crucial in the pathogenesis of atherosclerosis, thus new therapeutic approaches emerging that target NLRP3 inflammation. Here, we explored anti-atherosclerotic effect mechanisms rutaecarpine derivative, 5-deoxy-rutaecarpine (R3) vitro vivo. R3 treatment attenuated atherosclerosis development increased...

10.1096/fj.201900903rrr article EN The FASEB Journal 2019-12-01

Aberrant epigenetic modifications are fundamental contributors to the pathogenesis of various cancers. Consequently, targeting these aberrations with small molecules, such as histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors, presents a viable strategy for cancer therapy. The objective this study is assess anti-cancer efficacy trichostatin C (TSC), an analogue A sourced from fermentation Streptomyces sp. CPCC 203909. Our investigations reveal that TSC...

10.3390/ph17040425 article EN cc-by Pharmaceuticals 2024-03-27
Coming Soon ...